Email Us
Call Us
Pharmacokinetic and pharmacodynamic studies connect what the body does to a compound with what the compound does to the body. Measured separately, each answers half a question. Measured together in the same animals, they establish the exposure-response relationship that determines dose, schedule, and ultimately whether a compound has a workable therapeutic window.
Altogen Labs designs and conducts integrated PK/PD studies as standalone pharmacology programs or built into efficacy studies, so that exposure, target modulation, and tumor response are captured within a single protocol. To discuss an integrated design, request a quote.
Why integration changes the answer
Consider a compound that produces target modulation at four hours after dosing and none at twenty-four. Measured against time alone, this reads as a transient and possibly unimpressive effect. Measured against concentration, it may read as complete target engagement sustained for as long as the compound remains above threshold, with the limitation residing in half-life rather than in potency. Those two interpretations lead to different programs: one reformulates or redesigns the molecule, the other abandons it.
Separating the measurements across different studies, animals, or providers makes that distinction difficult to draw with confidence, because differences in animal, handling, and timing become confounded with the biology. Running both in the same subjects removes that confound.
Pharmacokinetic design
Studies include protocol-defined dosing, serial or terminal blood collection, plasma or serum preparation, and tissue collection at selected timepoints. Sampling schedules are set according to the expected exposure profile, route of administration, and analytical requirements, with timepoints concentrated where the profile changes fastest rather than spaced evenly for convenience.
Species selection is a design decision rather than a default. Sampling volume in the mouse constrains the number of timepoints obtainable from one animal and frequently requires composite sampling across a cohort. In the rat, a full time course can usually be taken from a single animal, which removes inter-animal variance from the profile and reduces the number of animals required. Where exposure is central to the question, this difference often determines which species the study should use.
Pharmacodynamic endpoints
Pharmacodynamic readouts are selected to match the mechanism and are sampled against the exposure time course rather than at a single convenient timepoint. Available endpoints include target gene expression, protein expression and phosphorylation state, pathway markers, cytokines, flow cytometric populations, immunohistochemistry, and tumor response.
The most informative pharmacodynamic endpoint is usually the one closest to the mechanism rather than the one easiest to measure. A downstream phenotypic readout confirms that something happened; a direct measure of target engagement establishes what.
Integrated oncology designs
For oncology programs, PK and PD sampling can be incorporated into cell line derived, patient-derived, syngeneic, humanized, orthotopic, and metastatic models. Satellite cohorts are commonly used where terminal sampling would otherwise compromise the efficacy arm, with the satellite animals treated identically and harvested at defined timepoints for tissue endpoints.
Applied examples
Target engagement duration. A kinase inhibitor is dosed once, with plasma concentration and tumor phosphoprotein levels measured at matched timepoints across twenty-four hours, defining the period of target suppression and thereby the dosing interval required for sustained inhibition.
Exposure-response across dose. Three dose levels are administered with both exposure and a pharmacodynamic marker measured in each, establishing whether the response plateaus within the tolerated range or continues to increase, which determines whether a higher dose would add benefit.
Immune pharmacodynamics. An immunotherapy is assessed with exposure measured alongside intratumoral effector populations and cytokine levels, relating the magnitude of immune activation to drug concentration rather than to dose administered.
Sample handling and analytical coordination
Altogen Labs coordinates blood sampling, necropsy and tissue collection, sample stabilization, and downstream molecular and pathology analysis according to the protocol and required matrices. Stabilization method is matched to the endpoint each sample will feed, decided before the study opens rather than at the bench, since a sample preserved for one assay is frequently unusable for another. All procedures are conducted under active IACUC protocols with sampling volumes and recovery intervals defined for the species. GLP standards are applied where a study is formally designated as GLP.
Send mechanism, proposed dose range, and pharmacodynamic marker, or request a quote.